Vitamin B12 Deficiency Anemia

Vitamin B12 (cobalamin) deficiency impairs DNA synthesis in rapidly dividing cells, producing a megaloblastic, macrocytic anemia — but its clinically most important feature is that it can independently cause serious, sometimes irreversible neurologic complications (subacute combined degeneration of the spinal cord, peripheral neuropathy, cognitive change) that may appear before anemia develops or without any hematologic abnormality at all. Deficiency most often results from malabsorption — pernicious anemia (autoimmune loss of intrinsic factor) is the classic cause — but can also be purely dietary, particularly in strict vegans. A clinically important, still under-appreciated point: current evidence supports high-dose oral cyanocobalamin as an effective first-choice treatment for most patients with B12 deficiency, including many with malabsorption, not only those with a clearly dietary cause.^[1]

• Pernicious anemia — autoimmune destruction of gastric parietal cells causing loss of intrinsic factor, which is required for B12 absorption in the terminal ileum.
• Other causes of malabsorption: atrophic gastritis, prior gastric or ileal surgery (including bariatric surgery), Crohn disease or other terminal ileal disease, chronic pancreatitis, small intestinal bacterial overgrowth, and long-term metformin or acid-suppressing therapy (proton pump inhibitors, H2-receptor antagonists).
• Strict vegan diet, or a vegetarian diet without adequate supplementation — vitamin B12 occurs naturally only in animal-source foods.
• Older age — reduced gastric acid and reduced intrinsic factor production are more common with age.
• Nitrous oxide exposure/misuse, which inactivates vitamin B12.
• Fish tapeworm (Diphyllobothrium latum) infection — competes for dietary B12.

History

• Diet (vegan/vegetarian pattern), prior GI surgery, known autoimmune disease (pernicious anemia clusters with other autoimmune conditions such as autoimmune thyroid disease and type 1 diabetes), alcohol use, and current medications (metformin, PPIs/H2-blockers, colchicine, anticonvulsants).
• Specifically ask about neurologic symptoms — numbness, tingling, balance problems, cognitive change — since these can be the only presenting feature.

Laboratory evaluation

• Serum cobalamin (B12) is the first-line test, but there is significant intra- and interindividual variation — patients with macrocytosis and a borderline B12 level need further assessment rather than being dismissed as normal. A level under 200 pmol/L is generally considered deficient or borderline deficient.
• Macrocytosis (MCV over 100 fL) with hypersegmented neutrophils on peripheral smear supports megaloblastic anemia, but a normal MCV does not exclude B12 deficiency, particularly when neurologic symptoms are the presenting feature or when concurrent iron deficiency masks the expected macrocytosis.
• Where diagnostic uncertainty remains, methylmalonic acid (elevated in true B12 deficiency, since B12 is a cofactor in its metabolism) can help clarify a borderline case.^[2]

• Correct hemoglobin and macrocytosis to normal.
• Halt progression of, and maximize recovery from, any neurologic manifestations.
• Establish and maintain an adequate long-term maintenance regimen appropriate to the underlying cause.

• Restoring normal dietary B12 intake (meat, fish, poultry, eggs, dairy) may be sufficient for purely dietary deficiency without malabsorption.
• Counsel strict vegans on reliable long-term B12 supplementation regardless of whether current levels are deficient, given the absence of any dietary source.
• Address contributing factors where feasible — reducing excessive alcohol intake, and reviewing whether a chronic acid-suppressing medication or metformin is truly still needed.

Pregnancy

With the exception of strict vegans, some vegetarians, and patients with malabsorption (including pernicious anemia), B12 is generally maintained at sufficient levels during pregnancy without supplementation; serum B12 can decrease physiologically in pregnancy without indicating true deficiency. When supplementation is needed, dosing is the same as in nonpregnant adults. No teratogenic effects are associated with B12 supplementation.

Breastfeeding

Compatible — B12 passes into breast milk at concentrations approximating maternal blood levels, and normal-dose supplementation is not associated with adverse effects in the infant.

Older adults

B12 deficiency is common in this population, often from reduced gastric acid or reduced intrinsic factor; oral high-dose therapy is effective and avoids the burden of regular injections when adherence can be reasonably ensured. Older patients on diuretics for heart failure are at particular risk of treatment-induced hypokalemia and need close potassium monitoring at treatment initiation.

Renal impairment

No specific dose adjustment is required for B12 itself, but monitor potassium especially closely if renal impairment coexists with diuretic use.

Expect a reticulocyte response within 3-4 days of starting effective therapy, with hemoglobin improving by about day 10 and full hematologic resolution within about 2 months. Check a baseline potassium level in at-risk patients (older adults on diuretics, severe anemia) before starting therapy, and monitor potassium closely in the first 48-72 hours, since rapid correction of severe megaloblastic anemia can cause a sudden, potentially profound drop in serum potassium as new blood cell production resumes.^[2] Reassess reticulocyte count, B12, and folate levels between days 5 and 7. Neurologic recovery is slower — improvement can take 6 months or longer, and some severe or longstanding deficits may not fully resolve, which is why prompt treatment at the first neurologic symptom matters.

1. Confirm adherence — this is the most common reason for an inadequate response to oral therapy specifically.
2. Check for concurrent iron or folate deficiency; concomitant iron deficiency can shift the MCV from macrocytic back toward the microcytic range and mask the expected response.
3. If adherence is confirmed but response remains inadequate on oral therapy, switch to parenteral therapy.
4. Reconsider the diagnosis and investigate for an alternative or additional cause of anemia and/or impaired erythropoietic response if the above steps do not explain a poor response.

• Waiting to confirm the exact cause of B12 deficiency before starting treatment in a patient with neurologic symptoms — start parenteral therapy without delay in that situation.
• Assuming a patient with malabsorption or pernicious anemia automatically needs lifelong injections — high-dose oral therapy is effective for most such patients if adherence is realistic.
• Treating B12 deficiency with folic acid alone, or failing to check B12 status before starting folic acid — see Folate Deficiency Anemia for why this is a distinct, important safety issue.
• Missing early hypokalemia when correcting severe megaloblastic anemia, particularly in an older patient on diuretics.
• Dismissing a borderline-normal B12 level in a patient with a strongly suggestive clinical picture.

How to use this table: Doses are adult doses and require patient-specific confirmation. Select any drug name to open its complete Pharmasist Drug Database page. Note: the Drug Database's "Hydroxocobalamin" entry (brand Cyanokit) is a high-dose IV cyanide-poisoning antidote, not a vitamin B12 replacement product, and is not referenced in this table.

Oral cyanocobalamin

Effective first choice for most patients, including most with malabsorption or pernicious anemia, provided daily adherence is realistic. Essentially nontoxic even at high doses — excess is renally excreted.

Parenteral cyanocobalamin

Reserved for neurologic symptoms requiring the fastest possible correction, confirmed nonadherence to oral therapy, or inability to reliably attend follow-up monitoring on an oral regimen. Given IM or deep SC only — never IV.

Evidence note: Drug inventory, dosing, adverse effects, and comments reflect current practice per the 2024 NICE NG239 guideline and the 2018 Cochrane review of oral versus intramuscular B12.^[1][3]